Leptomeningeal disease from melanoma—Poor prognosis despite new therapeutic modalities.

MLA

Chorti, Eleftheria, et al. “Leptomeningeal Disease from Melanoma—Poor Prognosis despite New Therapeutic Modalities.” European Journal of Cancer, vol. 148, May 2021, pp. 395–404. EBSCOhost, https://doi.org/10.1016/j.ejca.2021.02.016.

APA

Chorti, E., Kebir, S., Ahmed, M. S., Keyvani, K., Umutlu, L., Kanaki, T., Zaremba, A., Reinboldt-Jockenhoefer, F., Knispel, S., Gratsias, E., Roesch, A., Ugurel, S., Scheffler, B., Schadendorf, D., Livingstone, E., Meier, F., Glas, M., & Zimmer, L. (2021). Leptomeningeal disease from melanoma—Poor prognosis despite new therapeutic modalities. European Journal of Cancer, 148, 395–404. https://doi.org/10.1016/j.ejca.2021.02.016

Chicago

Chorti, Eleftheria, Sied Kebir, Misbah S. Ahmed, Kathy Keyvani, Lale Umutlu, Theodora Kanaki, Anne Zaremba, et al. 2021. “Leptomeningeal Disease from Melanoma—Poor Prognosis despite New Therapeutic Modalities.” European Journal of Cancer 148 (May): 395–404. doi:10.1016/j.ejca.2021.02.016.